2025년
한국질량분석학회 여름학술대회 및 총회
2025. 08.27 (수) ~ 2025. 08.29 (금)
부산항국제전시컨벤션센터(BPEX)
초록검색
| 제목 | Comparative Analysis of Stellar™ MS System and Triple Quad 6500+ System for Quantification of AFP and AFP-Fucose% |
|---|---|
| 작성자 | 이세영 ((재)씨젠의료재단) |
| 발표구분 | 포스터발표 |
| 발표분야 | 4. Medical / Pharmaceutical Science |
| 발표자 |
Saeyoung Lee (R&D Center for Clinical Mass Spectrometry, Seegene Medical Foundation) |
| 주저자 | Saeyoung Lee (R&D Center for Clinical Mass Spectrometry, Seegene Medical Foundation) |
| 교신저자 |
Je-Hyun Baek (R&D Center for Clinical Mass Spectrometry, Seegene Medical Foundation) |
| 저자 |
Saeyoung Lee (R&D Center for Clinical Mass Spectrometry, Seegene Medical Foundation) Yoonha Park (R&D Center for Clinical Mass Spectrometry, Seegene Medical Foundation) Juri Park (R&D Center for Clinical Mass Spectrometry, Seegene Medical Foundation) Hyojin Kim (R&D Center for Clinical Mass Spectrometry, Seegene Medical Foundation) Won Suk Yang (R&D Center for Clinical Mass Spectrometry, Seegene Medical Foundation) Je-Hyun Baek (R&D Center for Clinical Mass Spectrometry, Seegene Medical Foundation) |
|
Multiple Reaction Monitoring (MRM) has become a powerful approach for developing diagnostic assays targeting protein biomarkers, owing to its high sensitivity, multiplexing capabilities, and analytical specificity. However, MRM-based mass spectrometry often faces limitations in throughput, flexibility, and assay development time, particularly when screening multiple biomarker candidates. The Stellar™ MS system (Thermo Scientific), utilizing Parallel Reaction Monitoring (PRM), is emerging as a promising LC-MS/MS platform designed to expedite assay development workflows. To evaluate the performance, we compared the brand new PRM to conventional MRM (Triple Quad 6500+) using clinical serum samples (n = 509), addressing two hepatocellular carcinoma biomarkers: alpha-fetoprotein (AFP) and fucosylated AFP. Both methods showed strong calibration linearity for AFP (R² = 0.980) and excellent correlation in AFP quantification (R² = 0.998). Quantification of fucosylated AFP also exhibited high concordance between the two platforms (R² = 0.960). Notably, the Stellar™ MS system enabled completion of PRM-based assays for over 40 additional biomarker candidates within just two weeks. These results demonstrate that the PRM approach delivers quantification performance and clinical relevance comparable to established MRM methodologies. Furthermore, the PRM approach shows great promise as a flexible and time-efficient analytical platform for clinical diagnostics and biomarker discovery. |
|